Bristol Myers’ (BMY) is striving hard for the label expansion of its key drugs. The company’s growth portfolio comprises ...

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...

Despite not meeting the endpoint, subjects have experienced a meaningful improvement in RBC transfusion independence.

Bristol Myers' Reblozyl missed its primary goal in a Phase 3 anemia trial but showed positive secondary outcomes in ...

Despite the failure, BMS remains “encouraged” by Reblozyl’s clinical activity in myelofibrosis-associated anemia and will approach regulators to discuss potential submissions for this indication, for ...

Bristol Myers on Friday said the Phase 3 study of Reblozyl with concomitant janus-kinase-inhibitor therapy didn't meet its primary endpoint of red-blood-cell transfusion independence in adults with ...

Reblozyl® (luspatercept-aamt) is approved as first-line treatment of anemia in adults with very low- to intermediate-risk myelodysplastic syndromes.

Bristol Myers Squibb today announced that the European Commission has expanded approval of Reblozyl ® to include the first-line treatment of adult patients with transfusion-dependent anemia due ...

Bristol-Myers (BMY) and Acceleron Pharma Inc.'s sBLA for Reblozyl in patients with myelodysplastic syndromes will be reviewed by the FDA's Oncologic Drugs Advisory Committee.

Reblozyl is supplied as 25mg and 75mg lyophilized powder in single-dose vials for reconstitution and subcutaneous administration. The product is expected to be available in 1 week.

SUMMIT, N.J.& CAMBRIDGE, Mass.---- Celgene Corporation and Acceleron Pharma Inc. today announced the U.S. Food and Drug Administration has approved REBLOZYL ® for the treatment of anemia in adult ...

Reblozyl, which was approved last summer, led to more patients with myelodysplastic syndromes achieving 12- and 24-week intervals of red blood cell transfusion independence compared with epoetin alfa.